Komori
Occurring Fact4880CellSource Co.,Ltd.Pharmaceuticals

Notice Regarding the Recognition of Income Taxes—Deferred Tax Expense

During the cumulative third-quarter period of the fiscal year ending October 2026, deferred tax assets were reversed and an income tax adjustment loss of ¥38 million was recognized. The amount is reflected in the Summary of Third-Quarter Financial Results released on the same day.

Worth reading
37Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
38
million yen
Wording
Definitive
How definitive the wording is.

Recognition of deferred income tax expense (loss)

Subject Entity

CellSource Co., Ltd.

Target Locations / Products

Contract Processing Services

This disclosure09/08/2026
Cause

Revenue, driven mainly by the priority area of contract processing services, exceeded the initial forecast, while quarterly net income increased and tax loss carryforwards decreased as a result of reductions in selling, general and administrative expenses through the selection and concentration of business operations, among other factors

Amount of Impact on Business Performance

¥38 million (income tax adjustment loss)

Accounting period in which recognized

Cumulative third-quarter period of the fiscal year ending October 2026 (1 November 2025 to 31 July 2026)

Impact on Earnings Forecast

Reflected in the Summary of Third-Quarter Financial Results for the Fiscal Year Ending October 2026 [Japanese GAAP] (Non-consolidated), released today

Event that occurred
ItemDetails
Event nameRecognition of deferred income tax expense (loss)
Subject EntityCellSource Co., Ltd.
Target Locations / ProductsContract Processing Services
CauseRevenue, driven mainly by the priority area of contract processing services, exceeded the initial forecast, while quarterly net income increased and tax loss carryforwards decreased as a result of reductions in selling, general and administrative expenses through the selection and concentration of business operations, among other factors
Amount of Impact on Business Performance¥38 million (income tax adjustment loss)
Accounting period in which recognizedCumulative third-quarter period of the fiscal year ending October 2026 (1 November 2025 to 31 July 2026)
Impact on Earnings ForecastReflected in the Summary of Third-Quarter Financial Results for the Fiscal Year Ending October 2026 [Japanese GAAP] (Non-consolidated), released today
Items this document does not state (18)
Date of occurrenceDate recognized / date notice receivedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changeOutlookPlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Quarterly net income increased as revenue, driven mainly by contract processing services, exceeded the initial forecast and selling, general and administrative expenses were reduced through the selection and concentration of business operations, resulting in a reduction in tax loss carryforwards.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Recognition of Income Taxes—Deferred Tax Expense | CellSource Co.,Ltd. (4880) timely disclosure | Komori